Alk-Abello As B Shs New (AKBLF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to the presentation of ALK's Q4 and full year 2025 results. My name is Per Plotnikoff. I'm head of investor relations, and thank you all for joining. On slide two, I will present the speakers and agenda for this call. And with me today are CEO Peter Halling and CFO Claus Steensen Sølje. Peter and Claus will walk you through the Q4 and full year highlights, market and product trends, as well as the full year financial performance. Then we will provide an update on the strategic progress and priorities before presenting our outlook for 2026. As usual, we will end with a Q&A session. And to get us started, I'll hand you over to Peter and slide number three. Please go ahead, Peter. Thank you, Peter. And thank you all for joining the call. We delivered a solid performance in the fourth quarter, leading us to end 2025 at the very top end of our latest outlook. So let me start out by highlighting three key strategic developments in the quarter. Firstly, the pediatric rollout of our house dust mite and tree pollen tablets, Acarisax and Etudasax, provides wider access to prescribers in key markets and continue to perform very well. Secondly, the European rollout of Euronefi, or just Nefi, continues following our initial launch in Germany in late June. At the end of 2025, Euronefi achieved an 18% value share in Germany. And since then, we have now also launched in the UK. And by year end, market access was also in place in Greece, Denmark, Slovenia, with launches expected shortly. While we are still in the early phases, the initial market response to Nefi supports the product's long-term potential. At the same time, established clinical practices still favor traditional anaphylaxis treatments, and we will continue working diligently with the medical communit...